In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
REGULATORY
Japan Ambassador Meets Astellas Employee Detained in China
Japanese Ambassador to China Hideo Tarumi on November 28 met with a Japanese employee of Astellas Pharma who was taken into custody in Beijing earlier this year over spying allegations, according to diplomatic sources. The employee in his 50s told…
To read the full story
Related Article
- Japan Will Persistently Urge China to Release Detained Astellas Employee: Govt
April 12, 2024
- 1 Year on, China Mulling Potential Indictment of Detained Astellas Employee
March 22, 2024
- China Formally Arrests Astellas Employee, Japan Urges Immediate Release
October 20, 2023
- China to Soon Decide Whether to Arrest Detained Japanese Astellas Employee
September 21, 2023
- Japan Embassy Granted First In-Person Visit to Detained Astellas Employee
July 24, 2023
- China Envoy Says Spying Allegations of Astellas Employee Becoming Certain
April 10, 2023
- Japanese Embassy Official Meets Astellas Employee Detained in China
April 5, 2023
- Japanese Foreign Minister Demands Release of Man Detained in China
April 3, 2023
- Japan’s Foreign Minister Likely to Visit China Soon, Demand Citizen’s Release
March 29, 2023
- Japan Industry Frets Fate of Astellas Worker Held in China for Espionage Allegation
March 28, 2023
- Japanese Man Detained in China was Astellas Employee
March 27, 2023
REGULATORY
- PMDA-Led Inspections Will Help Straighten Up Generic Makers: MHLW Councilor
September 6, 2024
- MOF Intent on Expanding Scope of Off-Year Revision in 2025: Budget Examiner
September 6, 2024
- Trodelvy Up for Japan Panel Review on Sept. 12, Meiji COVID Jab on Agenda Too
September 6, 2024
- Japan to Prepare Fact Sheets on RSV Vaccine, Antibody
September 5, 2024
- Japan Poised to Launch FIH Trial System in FY2029 to Attract Global Seeds
September 5, 2024
An increasing number of companies in Japan are showing an eagerness to snatch up “drug loss” assets. As of this…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…